Скачать или смотреть “Remarkable” Phase 2 Oxylanthanum Carbonate Data, With Pablo Pergola, MD, PhD

Hyperphosphatemia remains a common and clinically important challenge for individuals with chronic kidney disease (CKD) undergoing dialysis. Although phosphate binders play a critical role in helping regulate phosphate levels, their utility is often hampered by large pill sizes, high daily pill counts, strict dosing requirements, and gastrointestinal intolerance. These barriers frequently lead to poor adherence, limiting their effectiveness in long-term disease management.

“When you talk about efficacy… there are several things that affect how you can get that done. One is the potency, so how well the medication works in binding the phosphate from the intestine. But a very potent drug that you cannot take doesn't work. If it sits on the counter or on your table, then the efficacy is zero,” Pablo Pergola, MD, PhD, research director of the Clinical Advancement Center at Renal Associates PA, explained to HCPLive. “You need to have something that's potent that the patients can take, so it relates to that pill burden, availability, and accessibility, so the patient can take it, they tolerate it, and it works. Then you get the efficacy that you need.”

Oxylanthanum carbonate (OLC), an investigational lanthanum-based phosphate binder, has been developed using nanoparticle technology designed to minimize pill size and reduce overall pill burden. Findings from a phase 2, open-label, single-arm, multicenter trial published in the Clinical Journal of the American Society of Nephrology point to OLC’s potential as a promising new therapy for managing hyperphosphatemia in patients with CKD receiving dialysis.

Full article: https://www.hcplive.com/view/-remarka...

#Nephrology #CKD #Doctor #Medicine